Mountain View, CA, United States of America

Annie L Lennek

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.6

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Annie L Lennek in RAS Modulation

Introduction

Annie L Lennek is a prominent inventor based in Mountain View, CA (US). She has made significant contributions to the field of biotechnology, particularly in the modulation of RAS GTPase, which plays a crucial role in various diseases, including cancer. With a total of two patents to her name, Lennek's work is paving the way for new therapeutic approaches.

Latest Patents

Annie L Lennek's latest patents include innovative compounds and methods for modulating RAS activity. The first patent focuses on modulators of RAS GTPase, providing compounds that can inhibit the growth of cancer cells driven by kRAS or mutated kRAS. These compounds are designed to treat RAS-driven diseases by administering a therapeutically effective amount. Additionally, the patent includes pharmaceutical compositions and kits that incorporate these compounds. The second patent involves pyrazolopyrimidine modulators of RAS GTPase, which also target mutant RAS implicated in diseases. Similar to the first, these compounds aim to inhibit cancer cell growth and provide methods for treating RAS-driven diseases.

Career Highlights

Annie L Lennek is associated with Tosk, Incorporated, where she continues to advance her research and development efforts. Her work is characterized by a strong focus on creating effective treatments for diseases associated with RAS mutations.

Collaborations

Some of her notable coworkers include Stephen D Yanofsky and Solomon B Ungashe, who contribute to her innovative projects and research initiatives.

Conclusion

Annie L Lennek's contributions to RAS modulation represent a significant advancement in the field of biotechnology. Her innovative patents and collaborative efforts are essential in the ongoing fight against RAS-driven diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…